 | Up a level |
Becker, H. J., Reuter, S., Marquez, Garcia M., Schloesser, H. A., von Bergwelt-Baildon, M. and Theurich, S. (2016). B cells derived from patients with von Hippel-Lindau (VHL) disease display impaired antigen presentation upon CD40 activation. Oncol. Res. Treat., 39. S. 271 - 272. BASEL: KARGER. ISSN 2296-5262
Chakupurakal, G., Garcia-Marquez, M., Shimabukuro vorn-hagen, A., Schloesser, H., Holtick, U., Scheid, C. and von Bergwelt-Baildon, M. (2015). Changes in T and B- cells in steroid refractory GvHD patients following treatment with a CD25-antibody. Bone Marrow Transplant., 50. S. S177 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Chakupurakal, G., Garcia-Marquez, M., Shimabukuro vorn-hagen, A., Schloesser, H., Holtick, U., Scheid, C. and von Bergwelt-Baildon, M. (2015). Changes in T and B- cells in steroid refractory GvHD patients following treatment with a CD25-antibody. Bone Marrow Transplant., 50. S. S177 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Chakupurakal, G., Garcia-Marquez, M., Shimabukuro-Vorn-hagen, A., Theurichi, S., Scheid, C., Hallek, M., Holtick, U. and von Bergwelt-Baildon, M. (2015). IL-10 producing B-10 cells can be identified as early as 30 days post an allogeneic stem cell transplant and are enriched in the transitional B-cell compartment. Bone Marrow Transplant., 50. S. S176 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Chakupurakal, G., Garcia-Marquez, M., Shimabukuro-Vorn-hagen, A., Theurichi, S., Scheid, C., Hallek, M., Holtick, U. and von Bergwelt-Baildon, M. (2015). IL-10 producing B-10 cells can be identified as early as 30 days post an allogeneic stem cell transplant and are enriched in the transitional B-cell compartment. Bone Marrow Transplant., 50. S. S176 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Chakupurakal, G., Leitzke, S., Langerbeins, P., Schiller, J., Schneider, P. M., Holtick, U., Shimabukuro-Vornhagen, A., Theurich, S., Chemnitz, J., Hallek, M., von Bergwelt-Baildon, M. and Scheid, C. (2015). Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality-a single institution experience. Ann. Hematol., 94 (10). S. 1717 - 1726. NEW YORK: SPRINGER. ISSN 1432-0584
Fischer, R. N., Abdulla, D., Michels, S., Nogova, L., Brandes, V, Scheffler, M., Schaeffer, S., Scheel, A., Thurat, M., Vehreschild, M., Thomas, R., von Bergwelt-Baildon, M., Buettner, R. and Wolf, J. (2016). Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition. Oncol. Res. Treat., 39. S. 92 - 94. BASEL: KARGER. ISSN 2296-5262
Fischer, R. N., George, J., Schaefer, S., Scheel, A., Schloesser, H., Vehreschild, M., von Bergwelt-Baildon, M., Nogova, L., Abdulla, D. S. Y., Michels, S., Riedel, R., Scheffler, M., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kambartel, K., Kern, J., Kopp, H-G, Neukirchen, J., Overbeck, T. R., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Buettner, R., Thomas, R. and Wolf, J. (2018). BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer. Oncol. Res. Treat., 41. S. 270 - 272. BASEL: KARGER. ISSN 2296-5262
Fischer, R. N., Scheel, A. H., Rothschild, S., I, Schloesser, H. A., Wolf, J., Buettner, R., Ansen, S. and von Bergwelt-Baildon, M. (2015). Tumor-infiltrating B lymphocytes characterized by CD79a and MUM1 independently predict outcome in patients with non-small cell lung cancer. Oncol. Res. Treat., 38. S. 13 - 14. BASEL: KARGER. ISSN 2296-5262
Garcia Borrega, J., Heindel, K., Kochanek, M., Warnke, C., Stemmler, J., von Bergwelt-Baildon, M., Liebregts, T. and Boell, B. (2021). The critically ill CAR T-cell patient Relevant toxicities, their management and challenges in critical care. Med. Klin.-Intensivmed Notfallmed., 116 (2). S. 121 - 129. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2193-6226
Garcia-Marquez, M., Schloesser, H., Thelen, M., Zimmer, S. and von Bergwelt-Baildon, M. (2016). Characterization of infiltrating B cells in human colorectal and kidney cancer. Oncol. Res. Treat., 39. S. 157 - 158. BASEL: KARGER. ISSN 2296-5262
Garcia-Marquez, M. A., Thelen, M., Bauer, E., Wennhold, K., Lehmann, J., Keller, D., Gathof, B., Maas, L., George, J., Bruns, C., Quaas, A., von Bergwelt-Baildon, M., Peifer, M. and Schloesser, H. A. (2021). GENOMIC HLA HOMOZYGOSITY IS FREQUENT IN ESOPHAGEAL ADENOCARCINOMA AND RELATED TO LOW IMMUNOGENICITY. J. Immunother. Cancer, 9. S. A1 - 2. LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426
Heimann, S., Cornely, O. A., Meintker, L., Heinz, W., Schroeder, T., Vehreschild, M., Wisplinghoff, H., von Bergwelt-Baildon, M. and Vehreschild, J. (2014). Different Doses of Micafungin for Prophylaxis of Invasive Fungal Diseases: A Web-based Non-Interventional Trial in Four Large University Hospitals in Germany. Oncol. Res. Treat., 37. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262
Heimann, S. M., Vehreschild, M. J. G. T., Meintker, L., Heinz, W., Schroeder, T., von Bergwelt-Baildon, M., Cornely, O. A. and Vehreschild, J. J. (2014). Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany. Transpl. Infect. Dis., 16 (6). S. 968 - 975. HOBOKEN: WILEY. ISSN 1399-3062
Holtick, U., Frenzel, L., Froehlich, H., Shimabukuro-Vornhagen, A., Theurich, S., Claasen, J., Scheid, C., von Bergwelt-Baildon, M., Wendtner, C. and Chemnitz, J. (2014). INCREASED FUNCTIONAL T CELL DEFECTS IN PATIENTS WITH LOW CD4 COUNTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Bone Marrow Transplant., 49. S. S558 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Huelsemann, M. F., Patz, M., Beckmann, L., Brinkmann, K., Otto, T., Fandrey, J., Becker, H. J., Theurich, S., von Bergwelt-Baildon, M., Pallasch, C. P., Zahedi, R. P., Kashkar, H., Reinhardt, H. C., Hallek, M., Wendtner, C. M. and Frenzel, L. P. (2015). Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia, 29 (4). S. 981 - 985. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Huelsemann, M. F., Patz, M., Beckmann, L., Brinkmann, K., Otto, T., Fandrey, J., Becker, H. J., Theurich, S., von Bergwelt-Baildon, M., Pallasch, C. P., Zahedi, R. P., Kashkar, H., Reinhardt, H. C., Hallek, M., Wendtner, C. M. and Frenzel, L. P. (2015). Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia, 29 (4). S. 981 - 985. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Huelsemann, M. F., Theurich, S., Becker, H. J., Pallasch, C., von Bergwelt-Baildon, M., Hallek, M., Wendtner, C. -M and Frenzel, L. P. (2014). p38 controls sensitivity to BH3 mimetics in CLL via regulation of Mcl-1. Oncol. Res. Treat., 37. S. 222 - 223. BASEL: KARGER. ISSN 2296-5262
Kochanek, M., Boell, B., Shimabukuro-Vornhagen, A., Michels, G., Barbara, W., Hansen, D., Hallek, M., Faetkenheuer, G. and von Bergwelt-Baildon, M. (2015). Personal Needs of an Intensive Care Unit under Consideration of current Hygiene Guidelines An explorative Analysis. Dtsch. Med. Wochenschr., 140 (14). S. E136 - 6. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413
Kochanek, M., Shimabukuro-Vornhagen, A., Ruess, K., Beutel, G., Lueck, C., Kiehl, M., Schneider, R., Kroschinsky, F., Liebregts, T., Kluge, S., Schellongowski, P., von Bergwelt-Baildon, M. and Boell, B. (2020). Prevalence of cancer patients in German intensive care units. Med. Klin.-Intensivmed Notfallmed., 115 (4). S. 312 - 320. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2193-6226
Kochanek, M., Wendtner, C., Shimabukuro-Vornhagen, A., Boell, B. and von Bergwelt-Baildon, M. (2014). Intensivmedizinische Betreuung onkologischer Patienten. Dtsch. Med. Wochenschr., 139 (14). S. 690 - 693. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413
Kochanek, Matthias 
ORCID: 0000-0002-4766-4651, Schalk, E., von Bergwelt-Baildon, M., Beutel, G., Buchheidt, D., Hentrich, M., Henze, L., Kiehl, M., Liebregts, T., von Lilienfeld-Toal, M., Classen, A., Mellinghoff, S., Penack, O., Piepel, C. and Boell, B.
(2019).
Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
Ann. Hematol., 98 (5).
S. 1051 - 1070.
NEW YORK:
SPRINGER.
ISSN 1432-0584
Lechner, A., Schloesser, H., Rothschild, S., Thelen, M., Shimabukuro-Vornhagen, A., Beutner, D. and von Bergwelt-Baildon, M. (2016). Characterization of Tumor-associated B lymphocytes in head and neck squamous cell carcinoma. Oncol. Res. Treat., 39. S. 108 - 110. BASEL: KARGER. ISSN 2296-5262
Marquez, Ma Garcia, Thelen, M., Bauer, E., Wennhold, K., Lehmann, J., Keller, D., Maas, L., Nicolik, M., George, J., Zander, T., Schroeder, W., Mueller, P., Bruns, C., Thomas, R., Gathof, B., Quaas, A., Hillmer, A. M., Peifer, M., von Bergwelt-Baildon, M. and Schloesser, H. A. (2022). HEREDITARY HOMOZYGOSITY AND ALLELIC IMBALANCE OF HLA AS COMMON IMMUNE ESCAPE MECHANISMS IN ESOPHAGEAL ADENOCARCINOMA. J. Immunother. Cancer, 10. S. A38 - 1. LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426
Mellinghoff, S. C., Banck, J. C., Mueller, N., Thelen, M., Schloesser, H. A., Cornely, O. A. and von Bergwelt-Baildon, M. (2020). Immune checkpoint blockade for aspergillosis and mucormycosis co-infection. Mycoses, 63. S. 24 - 25. HOBOKEN: WILEY. ISSN 1439-0507
Pflug, N., Chakupurakal, G., Theurich, S., Holtick, U., Leitzke, S., Chemnitz, J., Scheid, C., Hallek, M. and von Bergwelt-Baildon, M. (2018). Addition of rituximab to nonmyeloablative allogeneic transplantation for CLL and Richter's transformation - a single center experience. Oncol. Res. Treat., 41. S. 102 - 103. BASEL: KARGER. ISSN 2296-5262
Pflug, N., Kluth, S., Vehreschild, J. J., Bahlo, J., Tacke, D., Biehl, L., Eichhorst, B., Fischer, K., Cramer, P., Fink, A. -M, von Bergwelt-Baildon, M., Hallek, M., Cornely, O. A. and Vehreschild, M. J. G. T. (2015). Impact of antibiotic treatment modulating the intestinal microbiota on the efficacy of antineoplastic treatment for chronic lymphatic leukaemia or relapsed lymphoma. Oncol. Res. Treat., 38. S. 175 - 176. BASEL: KARGER. ISSN 2296-5262
Preugszat, E., Thelen, M., Garcia-Marquez, M., Lehmann, J., Keller, D., von Bergwelt-Baildon, M. and Schloesser, H. A. (2021). CANCER-SPECIFIC DIFFERENCES OF TERTIARY LYMPHOID STRUCTURES AND CELLULAR RESPONSES AGAINST FREQUENTLY EXPRESSED CANCER TESTIS ANTIGENS. J. Immunother. Cancer, 9. S. A19 - 2. LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426
Prinz, J., Boell, B., von Bergwelt-Baildon, M., Burst, V., Becker, J. U., Carvalho-Fiel, D., Shimabukuro-Vornhagen, A. and Kochanek, M. (2021). Intoxication after Consumption of Antifreeze Mixture The Case of a Patient after repeated Ethylene Glycol Intoxication (vol 114, pg 159, 2019). Med. Klin.-Intensivmed Notfallmed., 116 (4). S. 360 - 361. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2193-6226
Prinz, J., Goedel, P., Shimabukuro-Vornhagen, A., von Bergwelt-Baildon, M., Kochanek, M., Borchmann, P. and Boell, B. (2018). Immune-related toxicity syndromes in patients treated with chimeric antigen receptor T cell therapy. Oncol. Res. Treat., 41. S. 87 - 88. BASEL: KARGER. ISSN 2296-5262
Probst, L., Kochanek, M., Shimabukuro-Vornhagen, A., von Bergwelt-Baildon, M., Vehreschild, J. J., Prinz, J. and Boell, B. (2018). Predictive accuracy of sepsis scores in hematological patients. Oncol. Res. Treat., 41. S. 209 - 210. BASEL: KARGER. ISSN 2296-5262
Scheid, C., Chemnitz, J., Herling, M., Pflug, N., Theurich, S., Burst, A., Leitzke, S., von Bergwelt-Baildon, M., Hallek, M. and Holtick, U. (2016). A ROLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL AGENTS FOR HODGKIN'S LYMPHOMA? Haematologica, 101. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Schlaak, M., Kurschat, P., Shimabukuro-Vornhagen, A., Scheid, C., Chemnitz, J., Stadler, R., von Bergwelt-Baildon, M. and Theurich, S. (2011). Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transpl. Immunol., 25 (2-3). S. 163 - 167. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 0966-3274
Schloesser, H. A., Thelen, M., Dieplinger, G., von Bergwelt-Baildon, A., Heiermann, N., Kleinert, R., Wahba, R., Ditt, V., Kurschat, C., Cingoez, T., Becker, J., Stippel, D. and von Bergwelt-Baildon, M. (2016). PROSPECTIVE ANALYSES OF CIRCULATING B-CELL SUBSETS IN ABO-COMPATIBLE AND ABO-INCOMPATIBLE KIDNEY TRANSPLANT RECIPIENTS. Transpl. Int., 29. S. 44 - 45. HOBOKEN: WILEY-BLACKWELL. ISSN 1432-2277
Schloesser, H. A., Thelen, M., Lechner, A., Gilles, R., Garcia-Marquez, M., Wennhold, K., Alakus, H., Schroeder, W., Moenig, S., Theurich, S., Shimabukuro-Vornhagen, A., Gathof, B., Drebber, U., Quaas, A., Bruns, C., Hoelscher, A. H. and von Bergwelt-Baildon, M. (2017). Tumor-associated B cells and humoral immune response in esophago-gastric adenocarcinoma. Oncol. Res. Treat., 40. S. 159 - 160. BASEL: KARGER. ISSN 2296-5262
Schlosser, H. A., Thelen, M., Dieplinger, G., von Bergwelt-Baildon, A., Garcia-Marquez, M., Reuter, S., Shimabukuro-Vornhagen, A., Wennhold, K., Haustein, N., Buchner, D., Heiermann, N., Kleinert, R., Wahba, R., Ditt, V., Kurschat, C., Cingoz, T., Becker, J., Stippel, D. L. and von Bergwelt-Baildon, M. (2017). Prospective Analyses of Circulating B Cell Subsets in ABO-Compatible and ABO-Incompatible Kidney Transplant Recipients. Am. J. Transplant., 17 (2). S. 542 - 551. HOBOKEN: WILEY. ISSN 1600-6143
Shimabukuro-Vornhagen, A., Zoghi, S. and von Bergwelt-Baildon, M. (2017). Identification of the mevalonate pathway as a potential therapeutic target for EBV-reactivation and PTLD. Oncol. Res. Treat., 40. S. 263 - 264. BASEL: KARGER. ISSN 2296-5262
Suarez, I., Boell, B., Shimabukuro-Vornhagen, A., Michels, G., von Bergwelt-Baildon, M. and Kochanek, M. (2016). Mortality of hematology-oncology patients with neutropenia in intensivecare. Med. Klin.-Intensivmed Notfallmed., 111 (2). S. 84 - 92. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2193-6226
Thelen, M., Garcia-Marquez, M., Lehmann, J., Keller, D., Preugszat, E., von Bergwelt-Baildon, M. and Schloesser, H. A. (2021). ENDOGENOUS T-CELL RESPONSES TO TEN MAJOR CANCER TESTIS ANTIGENS ARE FREQUENT IN ESOPHAGO-GASTRIC ADENOCARCINOMA AND ANTIGEN-SPECIFIC T CELLS CAN BE EXPANDED USING CD40-ACTIVATED B CELLS. J. Immunother. Cancer, 9. S. A21 - 1. LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426
Thelen, M., Keller, D., Lehmann, J., Wennhold, K., Weitz, H., Bauer, E., Gathof, B., Brueggemann, M., Kotrova, M., Quaas, A., Mallmann, C., Chon, S., Hillmer, A. M., Bruns, C., von Bergwelt-Baildon, M., Garcia-Marquez, M. A. and Schloesser, H. A. (2022). IMMUNE RESPONSES AGAINST SHARED ANTIGENS ARE COMMON IN ESOPHAGO-GASTRIC CANCER AND CAN BE ENHANCED USING CD40-ACTIVATED B CELLS. J. Immunother. Cancer, 10. S. A24 - 1. LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426
Thelen, M., Lechner, A., Schloesser, H., Rothschild, S., Wennhold, K., Beutner, D. and von Bergwelt-Baildon, M. (2017). Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma (HNSCC). Oncol. Res. Treat., 40. S. 251 - 252. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Becker, H. J., Malcher, J., Marquez, M. G., Wennhold, K., Reuter, S., Shimabukuro-Vornhagen, A., Schloesser, H. A., Huelsemann, M., Frenzel, L. P. and von Bergwelt-Baildon, M. (2017). Hypoxia and iron-chelation decrease antigen-presenting functions in CD40-activated human B cells. Oncol. Res. Treat., 40. S. 255 - 256. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Iltgen, J., Wennhold, K., Marquez, M. Garcia, Rothschild, S., Schneider, B., Holtick, U., Thelen, M., Scheid, C., Becker, Hj, Schloesser, H., Reuter, S., Vornhagen, A. Shimabukuro and von Bergwelt-Baildon, M. (2016). THE JAK1/2 INHIBITOR RUXOLITINIB MODULATES ANTIGEN PRESENTING FUNCTIONS OF ACTIVATED PRIMARY B CELLS ON A METABOLIC LEVEL. Haematologica, 101. S. 462 - 463. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Theurich, S., Iltgen-Brebuda, J., Thelen, M., Wennhold, K., Rothschild, S., Becker, H., Schloesser, H., Shimabukuro-Vornhagen, A. and von Bergwelt-Baildon, M. (2017). Ruxolitinib modulates the antigen presenting function of activated B cells by interfering with metabolic pathways. Oncol. Res. Treat., 40. S. 262 - 263. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Mueller, P., Martin, K., Savic, S., Terszowski, G., Lardinois, D., Schlaak, M., Stadler, R., Kvasnicka, H. -M., Spagnoli, G., Dirnhofer, S., Speiser, D. E., von Bergwelt-Baildon, M. and Zippelius, A. (2014). Beyond cytotoxicity: Implications for immune mediated mechanisms of action of brentuximab vedotin treatment in CD30(+) lymphomas. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Rothschild, S. I., Hoffmann, M., Fabri, M., Sommer, A., Marquez, M. Garcia, Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., von Bergwelt-Baildon, M. and Schlaak, M. (2016). Cytotoxic local tumor treatment in combination with xystemic Ipilimumab enhances the efficacy of this immunotherapy and prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Rothschild, S., I, Hoffmann, M., Fabri, M., Sommer, A., Garcia-Marquez, M., Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., Borggrefe, J., Schlaak, M. and von Bergwelt-Baildon, M. (2016). Local treatment of tumors or metastases in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 103 - 105. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Rabenhorst, A., Hartmann, K., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Exp. Dermatol., 23 (3). S. E25 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262
Trommer-Nestler, M., Yeo, S. Y., Marnitz, S., Persigehl, T., Bunck, A., Schlaak, M., Gruell, H., Theurich, S., von Bergwelt-Baildon, M., Herter, J., Celik, E., Rosenbrock, J. and Baues, C. (2018). Abscopal effects in metastasized cancer patients treated with PD-1 inhibition and radiation therapy. Strahlenther. Onkol., 194. S. S200 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X
Wennhold, K., Thelen, M., Garcia-Marquez, M., Shimabukuro-Vornhagen, A. and von Bergwelt-Baildon, M. (2016). Tumorantigen-specific CD40B cells - combining enhanced antigen-presentation and antibody-secretion for tumor targeting. Oncol. Res. Treat., 39. S. 7 - 8. BASEL: KARGER. ISSN 2296-5262
Wennhold, K., Thelen, M., Lechner, A., Schloesser, H. and von Bergwelt-Baildon, M. (2018). CD86+antigen-presenting B cells are increased in solid cancers and induce tumor antigen-specific T cell responses. Oncol. Res. Treat., 41. S. 235 - 236. BASEL: KARGER. ISSN 2296-5262
Wennhold, K., Thelen, M., Schloesser, H., Shimabukuro-Vornhagen, A. and von Bergwelt-Baildon, M. (2017). Using antigen-specific B cells to combine antibody and T cell based cancer immunotherapy. Oncol. Res. Treat., 40. S. 241 - 242. BASEL: KARGER. ISSN 2296-5262
Wennhold, K., Thelen, M., Shimabukuro-Vornhagen, A. and von Bergwelt-Baildon, M. (2015). In vitro and in vivo imaging of the migratory behavior of tumorantigen-specific CD40-activated B cells in the setting of B cell-based cancer immunotherapy. Oncol. Res. Treat., 38. S. 170 - 171. BASEL: KARGER. ISSN 2296-5262
Zimmer, S., Schloesser, H., Wennhold, K., Thelen, M., Garcia-Marquez, M. and von Bergwelt-Baildon, M. (2016). Characterization of B-cell subsets in renal cell carcinoma. Oncol. Res. Treat., 39. S. 19 - 20. BASEL: KARGER. ISSN 2296-5262
von Bergwelt-Baildon, M., Holtick, U., Hallek, M. J. and Scheid, C. (2014). Hematopoietic stem cell transplantation. Bone marrow and blood stem cells. Internist, 55 (11). S. 1306 - 1313. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289